Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...
Discover how lightweight, stateless Thin Clients with read-only OS architectures support compliance, extend hardware lifespan ...
In a quarterly report filed with the U.S. Securities and Exchange Commission on November 14, 2025 ( SEC filing ), TREMBLANT CAPITAL GROUP disclosed a new position in CyberArk Software Ltd.
Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...
Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...
The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.
Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.
Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...
AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine's valuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results